{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:26:30Z","timestamp":1777577190266,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"34","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T00:00:00Z","timestamp":1562630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.vaccine.2019.03.036","type":"journal-article","created":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T16:45:37Z","timestamp":1564159537000},"page":"4778-4783","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["How can controlled human infection models accelerate clinical development and policy pathways for vaccines against Shigella?"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2555-7756","authenticated-orcid":false,"given":"Birgitte K.","family":"Giersing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chad K.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Kotloff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter","family":"Neels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Cravioto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Calman A.","family":"MacLennan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.vaccine.2019.03.036_b0005","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1473-3099(15)00068-7","article-title":"Design, recruitment, and microbiological considerations in human challenge studies","volume":"15","author":"Darton","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2019.03.036_b0010","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1016\/S1473-3099(18)30177-4","article-title":"Experimental infection of human volunteers","volume":"18","author":"Roestenberg","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"49 Pt A","key":"10.1016\/j.vaccine.2019.03.036_b0015","doi-asserted-by":"crossref","first-page":"6813","DOI":"10.1016\/j.vaccine.2017.05.068","article-title":"Developing and utilizing controlled human models of infection","volume":"35","author":"Porter","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.03.036_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.biologicals.2018.02.002","article-title":"Human challenge trials in vaccine development, Rockville, MD, USA, September 28\u201330, 2017","author":"Baay","year":"2018","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2019.03.036_b0025","doi-asserted-by":"crossref","first-page":"70","DOI":"10.12688\/wellcomeopenres.12256.1","article-title":"A framework for Controlled Human Infection Model (CHIM) studies in Malawi: Report of a Wellcome Trust workshop on CHIM in Low Income Countries held in Blantyre, Malawi","volume":"2","author":"Gordon","year":"2017","journal-title":"Wellcome Open Res"},{"issue":"11","key":"10.1016\/j.vaccine.2019.03.036_b0030","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/cid\/ciw145","article-title":"Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with vibrio cholerae O1 El Tor","volume":"62","author":"Chen","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.03.036_b0035","doi-asserted-by":"crossref","unstructured":"Typhoid vaccines: WHO position paper \u2013 March 2018, WER, 13, 2018, 93. Weekly Epidemiol Rec, 2018. WER 13 2018;93(13):153\u201372.","DOI":"10.1038\/s41565-018-0078-2"},{"issue":"3","key":"10.1016\/j.vaccine.2019.03.036_b0040","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/civ295","article-title":"Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study","volume":"61","author":"Mohan","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2019.03.036_b0045","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1128\/CVI.00532-10","article-title":"The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines","volume":"18","author":"Thiem","year":"2011","journal-title":"Clin Vaccine Immunol"},{"issue":"10111","key":"10.1016\/j.vaccine.2019.03.036_b0050","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/S0140-6736(17)32149-9","article-title":"Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial","volume":"390","author":"Jin","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.03.036_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(18)30475-4","article-title":"Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990\u20132016","author":"Khalil","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.03.036_b0060","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/ajgsup.2016.9","article-title":"Chronic health consequences of acute enteric infections in the developing world","volume":"3","author":"Colombara","year":"2016","journal-title":"Am J Gastroenterol Suppl"},{"key":"10.1016\/j.vaccine.2019.03.036_b0065","unstructured":"Organization WH. Global priority list of antibiotic-resistant bacteria to guide research, discovery and development of new antibiotics, 2017; Available from: https:\/\/www.who.int\/medicines\/publications\/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1."},{"key":"10.1016\/j.vaccine.2019.03.036_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2016.10.090","article-title":"Report from the world health organization's third product development for vaccines advisory committee (PDVAC) meeting, Geneva, 8\u201310th June 2016","author":"Giersing","year":"2017","journal-title":"Vaccine"},{"issue":"9046","key":"10.1016\/j.vaccine.2019.03.036_b0075","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(96)06255-1","article-title":"Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults","volume":"349","author":"Cohen","year":"1997","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.vaccine.2019.03.036_b0080","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.vaccine.2009.12.050","article-title":"Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children","volume":"28","author":"Passwell","year":"2010","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2019.03.036_b0085","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/cid\/ciu468","article-title":"Shigella isolates from the global enteric multicenter study inform vaccine development","volume":"59","author":"Livio","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2019.03.036_b0090","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1128\/CVI.00224-16","article-title":"Safety and immunogenicity of a candidate bioconjugate vaccine against shigella flexneri 2a administered to healthy adults: a single-blind, randomized phase I study","volume":"23","author":"Riddle","year":"2016","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2019.03.036_b0095","article-title":"Flexyn2a, a candidate bioconjugate vaccine against Shigella flexneri 2a induces protective immune response in a controlled human infection model","author":"Talaat","year":"2017","journal-title":"Vacc Enteric Dis"},{"key":"10.1016\/j.vaccine.2019.03.036_b0100","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ebiom.2017.07.013","article-title":"Safety profile and immunologic responses of a novel vaccine against Shigella sonnei administered intramuscularly, intradermally and intranasally: results from two parallel randomized phase 1 clinical studies in healthy adult volunteers in Europe","volume":"22","author":"Launay","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2019.03.036_b0105","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.3389\/fimmu.2017.01884","article-title":"A phase 2a randomized study to evaluate the safety and immunogenicity of the 1790GAHB generalized modules for membrane antigen vaccine against Shigella sonnei administered intramuscularly to adults from a shigellosis-endemic country","volume":"8","author":"Obiero","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2019.03.036_b0110","article-title":"A phase I dose escalation study to assess the safety and immunogenicity of the SF2a-TT15 conjugate vaccine against S. flexneri 2a in healthy adult volunteers (Preliminary Results)","author":"Cohen","year":"2017","journal-title":"Vacc Enteric Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2019.03.036_b0115","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00583-17","article-title":"Assembly, biochemical characterization, immunogenicity, adjuvanticity, and efficacy of shigella artificial invaplex","volume":"3","author":"Turbyfill","year":"2018","journal-title":"mSphere"},{"issue":"40","key":"10.1016\/j.vaccine.2019.03.036_b0120","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1016\/j.vaccine.2011.07.033","article-title":"Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine","volume":"29","author":"Riddle","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.03.036_b0125","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1001\/jama.1946.02870420002002","article-title":"Experimental human bacillary dysentery; polyvalent dysentery vaccine in its prevention","volume":"132","author":"Shaughnessy","year":"1946","journal-title":"J Am Med Assoc"},{"issue":"49","key":"10.1016\/j.vaccine.2019.03.036_b0130","doi-asserted-by":"crossref","first-page":"7040","DOI":"10.1016\/j.vaccine.2012.09.061","article-title":"Establishment of a Shigella sonnei human challenge model in Thailand","volume":"30","author":"Bodhidatta","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.03.036_b0135","unstructured":"Council for International Organizations of Medical Sciences (CIOMS) in collaboration with the World Health Organization (WHO): International Ethical Guidelines for Health-related Research Involving Humans, Guideline 17: Research involving children and adolescents, 2016."},{"key":"10.1016\/j.vaccine.2019.03.036_b0140","unstructured":"Standardization, W.H.O.E.C.O.B. Human Challenge Trials for Vaccine Development: regulatory considerations, 2016; Available from: https:\/\/www.who.int\/biologicals\/expert_committee\/Human_challenge_Trials_IK_final.pdf."},{"key":"10.1016\/j.vaccine.2019.03.036_b0145","unstructured":"Organization WH. From Vaccine development to policy: a brief review of WHO vaccine-related activities and advisory processes (2017), 2017; Available from: https:\/\/www.who.int\/immunization\/policy\/WHO_vaccine_development_policy.pdf."},{"key":"10.1016\/j.vaccine.2019.03.036_b0150","unstructured":"Organization WH. Principles and considerations for adding a vaccine to a national immunization programme: From decision to implementation and monitoring. 2014; Available from: http:\/\/www.who.int\/immunization\/programmes_systems\/policies_strategies\/vaccine_intro_resources\/nvi_guidelines\/en\/."},{"issue":"10031","key":"10.1016\/j.vaccine.2019.03.036_b0155","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/S0140-6736(16)30394-4","article-title":"Mind the gap: jumping from vaccine licensure to routine use","volume":"387","author":"O'Brien","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.03.036_b0160","unstructured":"Luthra K, J AZ, Vasudevan P, Privor-Dumm L. Pneumococcal conjugate Vaccine introduction and uptake timelines for Gavi supported countries. International symposium on pneumococci and pneumococcal diseases, 2018."},{"key":"10.1016\/j.vaccine.2019.03.036_b0165","unstructured":"Organization WH. WHO. Cholera vaccines. Weekly epidemiological record. Weekly Epidemiol Rec 2001;76: 117\u201324."},{"issue":"2","key":"10.1016\/j.vaccine.2019.03.036_b0170","first-page":"244","article-title":"Use of oral cholera vaccine in complex emergencies: what next? Summary report of an expert meeting and recommendations of WHO","volume":"25","author":"Chaignat","year":"2007","journal-title":"J Health Popul Nutr"},{"key":"10.1016\/j.vaccine.2019.03.036_b0175","unstructured":"Organization WH. Cholera vaccines: WHO position paper. Weekly Epidemiol Rec 2010;85: 117\u201328."},{"key":"10.1016\/j.vaccine.2019.03.036_b0180","unstructured":"Organization WH. Cholera vaccines: WHO position paper. Weekly Epidemiol Rec 2017;92: 477\u2013500."},{"issue":"8","key":"10.1016\/j.vaccine.2019.03.036_b0185","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1473-3099(17)30242-6","article-title":"Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial","volume":"17","author":"Groome","year":"2017","journal-title":"Lancet Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19303688?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19303688?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T16:45:51Z","timestamp":1564159551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19303688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":37,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0264410X19303688"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.03.036","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How can controlled human infection models accelerate clinical development and policy pathways for vaccines against Shigella?","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.03.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}